Filing Details
- Accession Number:
- 0001610717-24-000522
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-15 16:08:53
- Reporting Period:
- 2024-11-13
- Accepted Time:
- 2024-11-15 16:08:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1628171 | Revolution Medicines Inc. | RVMD | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1462808 | Michael Stephen Kelsey | C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-13 | 16,666 | $4.09 | 281,074 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-11-13 | 13,778 | $58.49 | 267,296 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-11-13 | 2,888 | $59.45 | 264,408 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-13 | 16,666 | $0.00 | 16,666 | $4.09 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
6,666 | 2023-03-13 | 2029-03-12 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
- Includes 86,400 restricted stock units.
- The transaction was executed in multiple trades in prices ranging from $58.13 to $59.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $59.13 to $59.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.